A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects

To evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of [14C]TAS-303 following oral single dose

Inclusion Criteria:Healthy adult male subjects who provided written informed consent to participate in the studyAged 18 years or older and younger than 40 years at the time of informed consentCapable of oral intake.Body weight of 50 kg or more and body mass index of 18.5 or more and less than 25.0Had blood pressure, pulse rate, and body temperature meeting any of the following at screening:Systolic blood pressure: ≧90 mmHg and ≦139 mmHg, Diastolic blood pressure: ≧40 mmHg and ≦89 mmHg, Pulse rate: ≧40 beats per minute (bpm) and ≦99 bpm, Body temperature: ≧35.0°C and ≦37.4°CExclusion Criteria:Had current or previous hypersensitivity or allergy to drugsHad current or previous drug abuse (including use of illicit drugs) or alcoholismHad any concurrent disease (including symptoms and signs; however, diseases that do not affect evaluations in the study such as asymptomatic pollinosis and wart are excluded)Received a radioisotope-labeled substance or subject to a large quantity of radiation exposure* within 12 months before the first dose of TAS-303.* A large quantity of radiation exposure includes continuous X-ray irradiation, computed tomography (CT) scan, gastric barium test, and positron emission tomography (PET) scan, excluding tests with low radiation exposure (e.g., chest, bone, or dental X-ray examination, or X-ray examination before boarding an airplane).Occupationally exposed to radiation within a year before the first dose of TAS-303 (such as operators who are involved in nuclear power or radiation operations).